TBIO (Codex DNA) Rentabilitas dodolan miturut bathi reged

Telesis Bio, Inc. (TBIO) leads in synthetic biology automation through its BioXp station and extensive R&D expenditures. Gross margin correlates with the adoption rate of benchtop synthesizers and demand for genetic engineering, while the 29.40 metric determines the status of the profitability parameter. The company's operations are strictly limited by FDA medical regulations and biomaterial disposal rules.
Rincian metrik komprehensif lan analitis Codex DNA (TBIO)

Telesis Bio, Inc. (TBIO) leadership in synthetic biology automation via the BioXp station requires strict control over direct production costs. Gross margin measures the portion of revenue remaining after deducting the cost of goods sold, reflecting the efficiency of scaling technological innovations and the issuer's pricing power. An analysis of gross income allows an investor to assess the company's ability to convert R&D investments into operating profit.